We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

US Stock IPO: Review of Chinese Companies That Submitted Applications for Listing in the US in the First 2 Months of 2023

US Stock IPO: Review of Chinese Companies That Submitted Applications for Listing in the US in the First 2 Months of 2023

Driven by a combination of positive factors, Chinese companies going public in the U.S. in the first two months of this year have been numerous.

U.S. listings include various methods such as IPO (Initial Public Offering), ADR (American Depositary Receipt), DPO (Direct Public Offering), and SPAC (Special Purpose Acquisition Company), with IPO, ADR, and SPAC being the most common.

As of February 28, in the first two months of this year, 15 Chinese companies publicly submitted IPO applications to the U.S. Securities and Exchange Commission (SEC), and 3 applied for listing via ADR. Among them, 2 have completed their listings.

23601d7464afbfa040d92fe60500d827_z+AFB6fO462IAAAAABJRU5ErkJggg==.png

Listed Companies

Hesai Technology officially submitted its listing application on January 17 this year, and listed on the NASDAQ on February 9, raising $190 million. It is the Chinese concept stock with the highest fundraising amount among the 4 Chinese companies that have gone public this year.

Hesai Technology is a global lidar R&D and manufacturing enterprise, whose products are widely used in passenger cars and commercial vehicles supporting Advanced Driver Assistance Systems (ADAS), as well as autonomous vehicles. It also covers various robot applications, such as unmanned delivery vehicles and logistics robots in closed areas.

Shockwave Therapeutics officially submitted its listing application on January 12 this year, and listed on the NASDAQ on February 3, raising $161 million.

Shockwave Therapeutics is a biopharmaceutical company focused on developing life-changing medicines for patients using advanced computing and structure-based technologies. The company is advancing differentiated therapeutic products in clinical stages, with a focus on chronic diseases with high unmet medical needs, such as cardiovascular, metabolic, and pulmonary diseases.

aad348386cc31c7db56b5a83c7558b5c_LNy8f8AZq7SL2FWoLYAAAAASUVORK5CYII=.png

In addition, this year Lotus Technology, Cheche Technology, Yisheng Biopharma, and Zero Yacht — a total of 4 companies — chose to go public in the U.S. via SPAC.

Among the companies that submitted IPO and ADR applications in the U.S. in the first two months, all chose the NASDAQ. The number was the highest in January, reaching 12. In terms of geographical distribution, Shenzhen and Shanghai rank at the top, with 5 and 4 companies respectively.

Companies that submitted IPO and ADR applications in the first two months

Findo Technology (FDAN), Shockwave Therapeutics (GPCR), Hesai (HSAI), Tiancheng Jinhui (TCJH), New Ruipeng (RPET), Ispire (ISPR), Yuezhonghui (YZH), Capital Circle (ZBJ), EWeiKe (EPWK), WeBus (WETO), Haoxin International (HXHX), Sitero (HARD), Inoz (ETZ), Green Health Group (HGRN), Jiayuda (JYD), NetEase Culture (NTV), Bestman (BSME), Rock Health (LGCL).

Originally published on 金盒企业管理集团